Clinical oncology最新文献_第9页

Impact of [18F]PSMA-1007 PET/CT on management of biochemical recurrence and high-risk staging of prostate cancer patients: A UK single centre experience

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.10.019

J. Korolewicz, D. Banerjee, M. Kimura, R. Kulshrestha, A. Challapalli

引用次数: 0

Corrigendum to ‘Paediatric Anatomical Models in Radiotherapy Applications’ [Clin Oncol (36) (2024) 562–575]

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103687

V. Apte , A. Ghose , C.A. Linares , S. Adeleke , V. Papadopoulos , E. Rassy , S. Boussios

引用次数: 0

RCR meetings

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2025.103775

引用次数: 0

Paid MBP advert Last chance to book_AI-Conference-A4-NHS_Final_02

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/S0936-6555(25)00034-2

引用次数: 0

A review of factors contributing to failure of deep inspiration breath hold in left breast radiotherapy

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103713

N. Doull, R. Stevens, K. Aitken, F. Sinclair, A. Armstrong

引用次数: 0

Whole brain radiotherapy in patients with metastatic breast cancer – is there a need to be selective?

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103725

S. Silverman, H. Li, K. Palmer, C. Guo, S. Needleman, C. Kane

引用次数: 0

A novel digital risk assessment tool in urgent suspected cancer pathways for breast cancer

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103726

A. Singh , O. Bandmann , K. Harwood , S. Tang , A. Andreou , K. Snape

引用次数: 0

Pitfalls of BRCA testing in historical and targeted samples: Quality and quantity both play a role in guidance of treatment management for PARP inhibition

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.10.011

N. Hill , S. Jain , D. Mitchell , J. O’Sullivan , D. O’Rourke , A. Cole

引用次数: 0

Pharmacogenomics: DPYD and Prevention of Toxicity 药物基因组学：DPYD和毒性预防。

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103706

J. Keen , J.H. McDermott , E. Aguilar-Martinez , W.G. Newman

{"title":"Pharmacogenomics: DPYD and Prevention of Toxicity","authors":"J. Keen , J.H. McDermott , E. Aguilar-Martinez , W.G. Newman","doi":"10.1016/j.clon.2024.103706","DOIUrl":"10.1016/j.clon.2024.103706","url":null,"abstract":"<div><div>In 2020, the introduction of pre-emptive <em>DPYD</em> genotyping prior to the administration of systemic fluoropyrimidine-based chemotherapy represented one of the first widespread pharmacogenetic testing programmes to be applied nationally in the United Kingdom. Pharmacogenetic variants in the <em>DPYD</em> gene found in between 3 and 6% of the population are a recognised cause of primary DPD enzyme deficiency and associated increased risk of severe fluoropyrimidine toxicity [1]. Yet, the availability of testing globally is heterogeneous. Despite growing evidence that in addition to reducing drug-induced toxicity, <em>DPYD</em>-guided dosing does not negatively affect outcomes, further research on the impact of routine <em>DPYD</em> genotyping in the UK population is required.</div><div>With mandatory testing in the UK focussed on four well-characterised variants, there is a need to address the applicability of this strategy across diverse ethnic or ancestral populations. We highlight approaches to identify and characterise rare variants in <em>DPYD</em> and in other genes involved in the pyrimidine metabolic pathway to reduce healthcare inequalities.</div><div>Finally, we discuss the future of pharmacogenomics within cancer care, and the potential to harness innovative digital and genotyping technologies to streamline prescribing and optimise both systemic anti-cancer therapies and supportive care.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103706"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Second-line treatment after CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer: What is the role of capecitabine? 激素受体阳性转移性乳腺癌CDK4/6抑制剂后的二线治疗：卡培他滨的作用是什么？

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103719

R. Mawella, C. Peters, A. Moss, R. Simcock, D. Bloomfield, G. Bertelli

引用次数: 0